IVERIC bio, Inc. announced the election of Christine Ann Miller to its Board of Directors, effective immediately. A global pharmaceutical veteran with more than 20 years of experience in life sciences, Ms. Miller is President and Chief Executive Officer of Melinta Therapeutics LLC, a company focused on the development and commercialization of innovative therapies for acute and life-threatening illnesses. Prior to her role at Melinta Therapeutics, where she also serves on the Board of Directors, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, where she was responsible for transitioning the portfolio toward rapid-growth and higher-margin segments such as complex generics and value-added medicines, while continuing to build the branded generics business.
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |